S'abonner

Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials - 28/04/23

Doi : 10.1016/j.ajog.2022.10.014 
Yuan-hui Liu, MD, PhD a, b, Ye-shen Zhang, MD a, b, Jia-yi Chen, MS c, Zhi-jian Wang, MD, PhD d, Yao-xin Liu, MD a, b, Jia-qi Li, MD d, Xiao-ji Xu, MD d, Nian-jin Xie, MD, PhD a, b, Stephen Lye, MD, PhD e, f, g, h, Ning Tan, MD, PhD a, b, , Chong-yang Duan, PhD c, Yan-xing Wei, MD, PhD d, e, f, g, h, Peng-cheng He, MD, PhD a, b, i,
a Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 
b Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 
c Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China 
d Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China 
e Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada 
f Departments of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada 
g Physiology, University of Toronto, Toronto, Canada 
h Medicine, University of Toronto, Toronto, Canada 
i Department of Cardiology, Heyuan People’s Hospital, Heyuan, China 

Corresponding authors: Ning Tan, MD, PhD.∗∗Peng-cheng He, MD, PhD.

Abstract

Objective

Preeclampsia is a common disease during pregnancy that leads to fetal and maternal adverse events. Few head-to-head clinical trials are currently comparing the effectiveness of prophylactic strategies for preeclampsia. In this network meta-analysis, we aimed to compare the efficacy of prophylactic strategies for preventing preeclampsia in pregnant women at risk.

Data Sources

Articles published in or before September 2021 from PubMed, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov, references of key articles, and previous meta-analyses were manually searched.

Study Eligibility Criteria

Randomized controlled trials comparing prophylactic strategies preventing preeclampsia with each other or with negative controls were included.

Methods

Two reviewers independently extracted data, assessed the risk of bias, and assessed evidence certainty. The efficacy of prophylactic strategies was estimated by frequentist and Bayesian network meta-analysis models. The primary composite outcome was preeclampsia/ pregnancy-induced hypertension.

Results

In total, 130 trials with a total of 112,916 patients were included to assess 13 prophylactic strategies. Low-molecular-weight heparin (0.60; 95% confidence interval, 0.42–0.87), vitamin D supplementation (0.65; 95% confidence interval, 0.45–0.95), and exercise (0.68; 95% confidence interval, 0.50–0.92) were as efficacious as calcium supplementation (0.71; 95% confidence interval, 0.62-0.82) and aspirin (0.79; 95% confidence interval, 0.72-0.86) in preventing preeclampsia/pregnancy-induced hypertension, with a P score ranking of 85%, 79%, 76%, 74%, and 61%, respectively. In the head-to-head comparison, no differences were found between these effective prophylactic strategies for preventing preeclampsia and pregnancy-induced hypertension, except with regard to exercise, which tended to be superior to aspirin and calcium supplementation in preventing pregnancy-induced hypertension. Furthermore, the prophylactic effects of aspirin and calcium supplementation were robust across subgroups. However, the prophylactic effects of low-molecular-weight heparin, exercise, and vitamin D supplementation on preeclampsia and pregnancy-induced hypertension varied with different risk populations, dosages, areas, etc. The certainty of the evidence was moderate to very low.

Conclusion

Low-molecular-weight heparin, vitamin D supplementation, exercise, calcium supplementation, and aspirin reduce the risk of preeclampsia/pregnancy-induced hypertension. No significant differences between effective prophylactic strategies were found in preventing preeclampsia. These findings raise the necessity to reevaluate the prophylactic effects of low-molecular-weight heparin, vitamin D supplementation, and exercise on preeclampsia.

Le texte complet de cet article est disponible en PDF.

Key words : network meta-analysis, preeclampsia, pregnancy-induced hypertension, prevention, prophylactic strategy


Plan


 Y.H.L., Y.S.Z., J.Y.C., and Z.J.W. share first authorship.
 N.T., C.Y.D., Y.X.W., and P.C.H. are considered as cocorresponding authors.
 The authors report no conflict of interest.
 The Shuangqing Talent Program Project of Guangdong Provincial People’s Hospital was the primary funding source of this study.
 This study was registered on the International Prospective Register of Systematic Reviews on October 4, 2021 (registration number: CRD42021274903).
 Data sharing: All datasets generated for this study are included in the Supplemental Material.


© 2022  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 228 - N° 5

P. 535-546 - mai 2023 Retour au numéro
Article précédent Article précédent
  • Perioperative complications of a transvaginal cervical cerclage in singleton pregnancies: a systematic review and meta-analysis
  • Charlotte E. van Dijk, Sofie H. Breuking, Sophie Jansen, Jacqueline C.E.J.M. Limpens, Brenda M. Kazemier, Eva Pajkrt
| Article suivant Article suivant
  • Gestational hypertension and “severe” disease: time for a change
  • Steven L. Clark, George A. Saade, Mary C. Tolcher, Michael A. Belfort, Dwight J. Rouse, John R. Barton, Robert M. Silver, Baha M. Sibai

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.